Press Releases

Filter Releases

Date	Title and Summary	View
Toggle SummaryNov 05, 2013	Onconova Therapeutics, Inc. Announces Timing for Third Quarter 2013 Financial Results and Conference Call	View HTML Onconova Therapeutics, Inc. Announces Timing for Third Quarter 2013 Financial Results and Conference Call 12.7 KB
Toggle SummarySep 06, 2013	Onconova Therapeutics, Inc. Reports Second Quarter 2013 Financial and Operational Results	View HTML Onconova Therapeutics, Inc. Reports Second Quarter 2013 Financial and Operational Results 24 KB
Toggle SummaryJul 30, 2013	Onconova Announces Closing of Initial Public Offering and Full Exercise of Over-Allotment Option	View HTML Onconova Announces Closing of Initial Public Offering and Full Exercise of Over-Allotment Option 14.3 KB
Toggle SummaryJul 29, 2013	Onconova Appoints Dr. Jerome Groopman and Anne VanLent to Board of Directors	View HTML Onconova Appoints Dr. Jerome Groopman and Anne VanLent to Board of Directors 14.3 KB
Toggle SummaryJul 25, 2013	Onconova Announces Pricing of Initial Public Offering	View HTML Onconova Announces Pricing of Initial Public Offering 13.4 KB
Toggle SummaryJun 14, 2013	Onconova Files Registration Statement for Proposed Initial Public Offering of Common Stock	View HTML Onconova Files Registration Statement for Proposed Initial Public Offering of Common Stock 13.8 KB
Toggle SummaryJun 01, 2013	Onconova Announces Presentation of Favorable Safety and Activity Data from Phase 2 Study of Oral Rigosertib in Lower Risk Myelodysplastic Syndromes Interim Results Presented at 2013 ASCO Annual Meeting Indicate Strong Signal of Transfusion Independence	View HTML Onconova Announces Presentation of Favorable Safety and Activity Data from Phase 2 Study of Oral Rigosertib in Lower Risk Myelodysplastic Syndromes 18.5 KB
Toggle SummaryMay 15, 2013	Onconova Announces Presentation of Oral Rigosertib Safety and Activity Data in Lower Risk Myelodysplastic Syndromes at the 2013 ASCO Annual Meeting	View HTML Onconova Announces Presentation of Oral Rigosertib Safety and Activity Data in Lower Risk Myelodysplastic Syndromes at the 2013 ASCO Annual Meeting 14.3 KB
Toggle SummaryMay 09, 2013	Onconova Completes Enrollment in ONTIME Pivotal Phase 3 Study of Rigosertib in Patients with High-risk Myelodysplastic Syndromes	View HTML Onconova Completes Enrollment in ONTIME Pivotal Phase 3 Study of Rigosertib in Patients with High-risk Myelodysplastic Syndromes 15.4 KB
Toggle SummaryApr 09, 2013	Onconova Announces Presentation of Positive Data of Oral Rigosertib in Advanced Head and Neck Cancer at AACR 2013 Annual Meeting Oral Rigosertib Progresses to Phase 2 Clinical Trial in Squamous Cell Head and Neck Cancers	View HTML Onconova Announces Presentation of Positive Data of Oral Rigosertib in Advanced Head and Neck Cancer at AACR 2013 Annual Meeting 17 KB